Leanne M Ward1, David R Weber2. 1. Division of Endocrinology and Metabolism, Children's Hospital of Eastern Ontario, Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada. 2. Division of Endocrinology and Diabetes, Golisano Children's Hospital, University of Rochester Medical Centre, Rochester, New York, USA.
Abstract
PURPOSE OF REVIEW: Glucocorticoid therapy is currently the most widely used treatment for Duchenne muscular dystrophy (DMD), having consistently shown to prolong ambulation by 2 years, reduce the frequency of scoliosis, and improve cardiorespiratory function. Among the most frequent side effects of glucocorticoids are fractures due to osteoporosis, linear growth retardation or arrest, and pubertal delay, the subjects of this review. RECENT FINDINGS: The diagnosis of osteoporosis has shifted in recent years away from a bone mineral density-centric to a fracture-focused approach, with particular emphasis on early vertebral fracture identification (one of the key triggers for osteoporosis intervention). Delayed puberty should be addressed in an age-appropriate manner, with numerous options available for sex steroid replacement. Growth impairment, however, is a more challenging complication of glucocorticoid-treated DMD, one that is most likely best addressed through growth-sparing therapies that target the dystrophinopathy. SUMMARY: With glucocorticoid prescription an increasingly prevalent component of DMD care, early attention to management of osteoporosis and delayed puberty are important components of multidisciplinary and anticipatory care. The treatment of short stature remains controversial, with no accepted therapy currently available to over-ride the toxic effects of glucocorticoids on the growth axis.
PURPOSE OF REVIEW: Glucocorticoid therapy is currently the most widely used treatment for Duchenne muscular dystrophy (DMD), having consistently shown to prolong ambulation by 2 years, reduce the frequency of scoliosis, and improve cardiorespiratory function. Among the most frequent side effects of glucocorticoids are fractures due to osteoporosis, linear growth retardation or arrest, and pubertal delay, the subjects of this review. RECENT FINDINGS: The diagnosis of osteoporosis has shifted in recent years away from a bone mineral density-centric to a fracture-focused approach, with particular emphasis on early vertebral fracture identification (one of the key triggers for osteoporosis intervention). Delayed puberty should be addressed in an age-appropriate manner, with numerous options available for sex steroid replacement. Growth impairment, however, is a more challenging complication of glucocorticoid-treated DMD, one that is most likely best addressed through growth-sparing therapies that target the dystrophinopathy. SUMMARY: With glucocorticoid prescription an increasingly prevalent component of DMD care, early attention to management of osteoporosis and delayed puberty are important components of multidisciplinary and anticipatory care. The treatment of short stature remains controversial, with no accepted therapy currently available to over-ride the toxic effects of glucocorticoids on the growth axis.
Authors: Luca Bello; Heather Gordish-Dressman; Lauren P Morgenroth; Erik K Henricson; Tina Duong; Eric P Hoffman; Avital Cnaan; Craig M McDonald Journal: Neurology Date: 2015-08-26 Impact factor: 9.910
Authors: Denise G M McDonald; Maria Kinali; Andrew C Gallagher; Eugenio Mercuri; Francesco Muntoni; Helen Roper; Philip Jardine; David Hilton Jones; M G Pike Journal: Dev Med Child Neurol Date: 2002-10 Impact factor: 5.449
Authors: David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; David Brumbaugh; Laura E Case; Paula R Clemens; Stasia Hadjiyannakis; Shree Pandya; Natalie Street; Jean Tomezsko; Kathryn R Wagner; Leanne M Ward; David R Weber Journal: Lancet Neurol Date: 2018-02-03 Impact factor: 44.182
Authors: Cuixia Tian; Brenda L Wong; Lindsey Hornung; Jane C Khoury; Lauren Miller; Jean Bange; Irina Rybalsky; Meilan M Rutter Journal: Neuromuscul Disord Date: 2016-08-22 Impact factor: 4.296
Authors: Elisabeth Sarrazin; Maja von der Hagen; Ulrike Schara; Katja von Au; Angela M Kaindl Journal: Eur J Paediatr Neurol Date: 2013-09-25 Impact factor: 3.140
Authors: Jean K Mah; Paula R Clemens; Michela Guglieri; Edward C Smith; Richard S Finkel; Mar Tulinius; Yoram Nevo; Monique M Ryan; Richard Webster; Diana Castro; Nancy L Kuntz; Craig M McDonald; Jesse M Damsker; Benjamin D Schwartz; Laurel J Mengle-Gaw; Stefan Jackowski; Georgia Stimpson; Deborah A Ridout; Vandana Ayyar-Gupta; Giovanni Baranello; Adnan Y Manzur; Francesco Muntoni; Heather Gordish-Dressman; Mika Leinonen; Leanne M Ward; Eric P Hoffman; Utkarsh J Dang Journal: JAMA Netw Open Date: 2022-01-04
Authors: Evellyn C Grilo; Thais A Cunha; Ádila Danielly S Costa; Bárbara G M Araújo; Márcia Marília G D Lopes; Bruna L L Maciel; Camila X Alves; Karina M Vermeulen-Serpa; Mário Emílio T Dourado-Júnior; Lucia Leite-Lais; José Brandão-Neto; Sancha Helena L Vale Journal: PLoS One Date: 2020-11-20 Impact factor: 3.240